Trial Profile
A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel Group Study to Evaluate the Efficacy and Safety of Ranolazine When Added to Metformin in Subjects With Type 2 Diabetes Mellitus [Randomizovane, dvojite zaslepene, placebem kontrolovane klinicke hodnoceni faze 3 s paralelnimi skupinami hodnotici ucinnost a bezpecnostRanolazinu pridaneho k Metforminu u pacientu s diabetes mellitus 2. typu]
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 07 Nov 2021
Price :
$35
*
At a glance
- Drugs Ranolazine (Primary) ; Metformin
- Indications Type 2 diabetes mellitus
- Focus Registrational; Therapeutic Use
- Sponsors Gilead Sciences
- 01 Sep 2013 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 10 Mar 2013 Top-line results are expected in late 2013 according to a Gilead Sciences media release.
- 16 Nov 2012 New source identified and integrated (Clinical Trials Registry - India; CTRI2012-11-003110).